Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$37.20M$37.20M+3.3% vs Q2 2024 Net Income-$2.38M-$2.38MN/M vs Q2 2024 EPS Diluted-$0.02-$0.02N/M vs Q2 2024 Gross Profit$27,343,000+7.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$10,868,000N/M Free Cash Flowderived-$11,076,000— Margins · derivedGross margin73.5%+2.7 pt vs Q2 2024
Operating margin-4.4%+13.5 pt vs Q2 2024
Net margin-6.4%+19.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 8, 2025 · 39 d after period end